

## Research Article

# Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of $\beta$ 2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

Yujie Zhang , Donghua He , Jingsong He , Weijia Huang , Yang Yang , Zhen Cai ,  
and Yi Zhao 

Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China

Correspondence should be addressed to Yi Zhao; zhaoyi999@zju.edu.cn

Received 29 October 2021; Accepted 14 December 2021; Published 20 January 2022

Academic Editor: Tao Huang

Copyright © 2022 Yujie Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Domestic bendamustine has been approved for appearing on the market in China in the past two years. The report on bendamustine plus rituximab (BR) in the treatment of Chinese B-cell-associated indolent non-Hodgkin's lymphoma (iNHL) has not yet been published. This study probed into clinical efficacy of the BR regimen for B-cell-associated iNHL in China as well as the value of  $\beta$ 2-microglobulin ( $\beta$ 2-MG) as a prognostic factor. **Methods.** We retrospectively analyzed clinical data of 73 B-cell-associated iNHL patients who received BR treatment in The First Affiliated Hospital, College of Medicine, Zhejiang University from January 2020 to January 2021, including clinical characteristics, therapies, therapeutic efficacy, and prognosis-related factors. Thirty-three patients (45.2%) did not receive any other treatment before the BR regimen, and other patients received CHOP, R-CHOP, and other regimens in the past. The cutoff date for follow-up was May 2021. Clinical characteristics of patients were analyzed. The clinical efficacy of the BR regimen was evaluated. Differences of  $\beta$ 2-MG expression before and after treatment were analyzed between the CR+PR group and the SD+PD group. Main outcomes were progression-free survival (PFS) and overall survival (OS). A multivariate Cox regression model was taken to analyze prognostic factors relative to survival rate of patients, and adverse events (AEs) during treatment. **Results.** The objective response rate (ORR) of B-cell-associated iNHL patients who received BR regimen as first-/multiline treatment was 79.5%, with complete response (CR) of 37.0%, partial response (PR) of 42.5%, median PFS of 12.1 months (95% confidence interval (CI): 10.9-13.2), and median OS of 15.5 months (95% CI: 14.8-16.1). Before treatment, there was no statistical significance in the  $\beta$ 2-MG level between the CR+PR group and the SD+PD group ( $p > 0.05$ ). After treatment, the  $\beta$ 2-MG level in the CR group was noticeably lower than that in the SD+PD group ( $p < 0.05$ ). The  $\beta$ 2-MG level in the CR+PR group decreased conspicuously after treatment ( $p < 0.05$ ). The  $\beta$ 2-MG level in the SD+PD group after treatment was not notably different from that before treatment ( $p > 0.05$ ). According to the median expression level of  $\beta$ 2-MG before treatment, patients were divided into two groups. The average PFS of the low expression group was  $12.69 \pm 0.77$  months, which was longer than the high expression group ( $10.13 \pm 0.74$  months), but the difference between the groups was not statistically significant ( $p > 0.05$ ). Multivariate Cox regression analysis showed that B-cell-associated iNHL subtype was the independent prognostic marker most likely to affect PFS of patients ( $p = 0.051$ ). Incidence of any grade of AEs in all patients was 32.9% (24/73). **Conclusion.** B-cell-associated iNHL patients who received BR regimen had favorable clinical efficacy and were tolerable to AEs. Though the  $\beta$ 2-MG level in this study could not be used to predict clinical outcome, a lower level before treatment seemed to be implicated in better survival outcomes of patients. Our research also unraveled that B-cell-associated iNHL subtype may be a key factor to patient's prognosis. Overall, this study offers some important insights into clinical application of the BR regimen for Chinese B-cell-associated iNHL patients.

## 1. Introduction

Lymphoma is one of the top 10 cancers in the world, including Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). The year 2017 witnessed 488,000 NHL cases and 249,000 NHL-related deaths worldwide [1]. NHL deriving from B-cells can be classified into B-cell-associated indolent NHL (iNHL) and B cell-associated invasive NHL in line with its invasiveness [2]. B-cell-associated iNHL includes follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), indolent mantle-cell lymphoma, Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia (CLL) [3]. These patients have relatively favorable survival outcomes, whereas advanced B-cell-associated iNHL is still considered incurable, which is called the iNHL paradox [2, 4]. In China, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen is generally taken as a first-line regimen for B-cell-associated iNHL treatment, but in western countries, bendamustine plus rituximab (BR) regimen has been approved for the first-line treatment of iNHL for many years [3, 5, 6]. Owing to poor outcomes of patients being refractory to the R-CHOP regimen, researchers engage in seeking novel treatment regimens.

Bendamustine as a novel alkylating agent has been approved for the treatment of iNHL including CLL [7–9]. The introduction of rituximab is believed to improve survival outcomes of FL patients [4]. Regimens containing rituximab have also been affirmed in the management of elderly patients with B-cell-associated iNHL [10]. Several randomized trials have demonstrated that the BR regimen can improve progression-free survival (PFS) compared with the R-CHOP regimen [11–13]. Indeed, data from several clinical trials have shown that the overall response rate ranges from 69 to 93% with the BR regimen [11, 14, 15]. Domestic bendamustine has been approved for appearing on the market in China in the past two years. The report on BR in the treatment of Chinese B-cell-associated indolent non-Hodgkin's lymphoma (iNHL) has not yet been published. Besides, the prognostic value of  $\beta 2$ -microglobulin ( $\beta 2$ -MG) in patients with NHL was evaluated previously. Kanemasa et al. [16] authenticated that  $\beta 2$ -MG level is a key prognosticator for patients with diffuse large B-cell lymphoma (DLBCL), but its clinical and prognostic significance in B-cell-associated iNHL remains to be elucidated.

To this end, we carried out a retrospective study on real-world data from the Chinese cohort and made a thorough inquiry into the clinical efficacy of BR regimen for B-cell-associated iNHL as well as the value of  $\beta 2$ -MG as a prognostic factor. Most clinical research regarding the BR regimen for iNHL is conducted in Western countries. Nevertheless, there is less clinical experience in China. Our investigation may be available for clinical practice of the BR regimen in China.

## 2. Materials and Methods

**2.1. Participants.** A retrospective analysis was carried out on clinical data from 73 patients with B-cell-associated iNHL

who received BR regimen in The First Affiliated Hospital, College of Medicine, Zhejiang University from January 2020 to January 2021. After admission, all patients required a bone marrow biopsy, ultrasound of superficial lymph nodes, and positron emission tomography-computed tomography (PET-CT) or enhanced CT scan. All patients were diagnosed by histopathological assessment and immunohistochemical study consistent with the 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms [17]. Classification of most types of lymphoma refers to the Lugano classification (2014) [18]. In addition, a method proposed by Rai et al. [19] or Binet et al. [20] was adopted for CLL classification. All collected patients met the following criteria: all patients were  $\geq 18$  years old; International Prognostic Index (IPI) was 1–5. The main exclusion criteria were as follows: patients who were intolerant to BR and then switched to other regimens; patients who had central nervous system lymphoma or primary mediastinal large B-cell lymphoma (PMBCL), with clear evidence of uncontrolled concomitant diseases. This study was approved by the Medical Ethics Committee of The First Affiliated Hospital, College of Medicine, Zhejiang University following the guidelines of the international coordination meeting (Good Clinical Practice; The Declaration of Helsinki).

**2.2. Procedures.** All patients received BR regimen as follows: 375 mg/m<sup>2</sup> rituximab (NMPN J20170034; Roche Pharma Ltd.), d1 of each cycle, administrated as an intravenous infusion (specification: 100 mg/10 mL), for 6 cycles (4 weeks a cycle); 75 mg/m<sup>2</sup> bendamustine (national medicine permission number (NMPN) H20193358; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.), d2~d3 of each cycle, administrated as an intravenous infusion (specification: 25 mg), for 6 cycles (4 weeks a cycle). Regimens were changed following clinical needs when the lymph node regression was found to be less than 50% or there was evidence of disease progression before the entire treatment plan was completed.

**2.3. Therapeutic Evaluation.** One day before treatment and one week after treatment, 5 mL fasting venous blood was collected from each subject in the morning, centrifuged to separate the serum, stored, and prepared at -80°C. The Automatic Hitachi 7080 Biochemistry Analyzer was implemented to assess serum  $\beta 2$ -MG level.

Based on Cheson's revised response criteria [21], treatment response was categorized as CR, partial response (PR), stable disease (SD), and progressive disease (PD). The primary efficacy endpoint was CR assessed by PET and Independent Review Committee (IRC) per Lugano classification (2014) [18]. Other outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Safety endpoints involved the incidence of all grades of adverse events (AEs).

**2.4. Follow-Up Visit.** Special personnel was in charge of following up all the patients through telephone, WeChat, QQ, and other communication methods. The follow-up visit was stopped in May 2021. PFS and OS of patients were

recorded (PFS: the time from the start of treatment to disease relapse or progression; OS: the time from the start of treatment to death or loss of follow-up).

**2.5. Statistical Analysis.** All statistical analyses were done using SPSS software (version 25.0; SPSS, Chicago, Illinois). Categorical variables were expressed as the number of cases and percentages. The chi-square test or Fisher's exact test was used for comparison between two categorical variables. Kolmogorov-Smirnov statistics were implemented to test the assumption of normality of continuous variables. If the data were normally or close to normally distributed, they were expressed as the mean (M)  $\pm$  standard deviation (SD). The independent-samples *t*-test compared scores on the same variable but for two different groups of cases. While the paired *t*-test compared scores on two different variables but for the same group of cases. Otherwise, the data were expressed as IQR. The Mann-Whitney *U* test was taken to compare the differences between two different groups. The Kaplan-Meier method was utilized to assess PFS and OS. The log-rank test was employed for PFS and OS comparison between two groups. Multivariate Cox regression analysis was handled to measure variables of dismal prognosis.  $p < 0.05$  was considered statistically significant.

### 3. Results

**3.1. Baseline Characteristics of Patients.** Among 73 patients, 40 (54.8%) patients received other therapeutic regimens previously. The common subtypes were follicular lymphoma (27.4%) (20/73), mantle cell lymphoma (23.3%) (17/73), mucosa-associated lymphoid tissue (24.7%, 18/73), and lymphocytic lymphoma (15.1%, 11/73). The median age of all patients was 62 (56–69). Baseline characteristics of patients are listed in Table 1.

**3.2. Clinical Efficacy.** ORR of patients who received BR regimen was 79.5%, with CR of 37.0% and PR of 42.5%. Median PFS was 12.1 months (95% confidence interval (CI): 10.9–13.2) (Table 2). Median OS was 15.5 months (95% CI: 14.8–16.1). Survival curves are illustrated in Figure 1.

**3.3. Changes of  $\beta 2$ -MG Level during Treatment.** Patients were classified into the CR+PR group and SD+PD patient according to whether patients achieved CR+PR. The independent samples *t*-test compared the  $\beta 2$ -MG level between the CR+PR group and the SD+PD group (CR+PR before treatment vs. SD+PD before treatment; CR+PR after treatment vs. SD+PD after treatment). As illustrated in Figure 2, there was no significant difference in the  $\beta 2$ -MG level between the CR+PR group and the SD+PD group before treatment ( $p > 0.05$ ). While after treatment, the  $\beta 2$ -MG level in the CR+PR group was lower than that in the SD+PD group ( $p < 0.05$ ). Afterward, paired *t*-tests compared  $\beta 2$ -MG level changes in the same group (CR+PR before treatment vs. CR+PR after treatment; SD+PD before treatment vs. SD+PD after treatment). As shown in Figure 3, the  $\beta 2$ -MG level in the CR+PR group was decreased conspicuously after treatment ( $p < 0.05$ ), and that in the SD+PD group

TABLE 1: Baseline characteristics of patients.

Characteristics	All patients, N = 73 (%)
Median age, years (IQR)	62 (56–69)
Sex, n (%)	
Male	41 (56.2)
Female	32 (43.8)
Histology, n (%)	
Mantle-cell lymphoma	17 (23.3)
Follicular lymphoma	20 (27.4)
Lymphocytic lymphoma (SLL/CLL)	11 (15.1)
Mucosa-associated lymphoid tissue	18 (24.7)
Other	7 (9.6)
Stage, n (%)	
I-II	13 (17.8)
III-IV	60 (82.2)
Prognostic groups for all patients (IPI), n (%)	
>2 risk factors	11 (15.1)
MIPI risk, n (%)	
Low ( $\leq 3$ )	4 (5.5)
Intermediate (4–5)	9 (12.3)
High ( $> 5$ )	4 (5.5)
FLIPI risk, n (%)	
Low ( $\leq 1$ )	5 (6.8)
Intermediate (2)	3 (4.1)
High (3–5)	12 (16.4)
ECOG performance status	
0~1	59 (80.8)
$\geq 2$	14 (19.2)
Number of previous treatments	
1	33 (45.2)
$\geq 2$	40 (54.8)
Prior chemotherapy, n (%)	37 (50.7)
Previous rituximab treatment, n (%)	31 (42.5)
$\beta 2$ -MG (mg/L)	3.25 (2.28–4.89)

Abbreviations: IPI = International Prognostic Index; MIPI = mantle cell lymphoma IPI; FLIPI = follicular lymphoma IPI.

TABLE 2: Clinical efficacy.

Response (n = 73)	n (%)
ORR	58 (79.5)
CR	27 (37.0)
PR	31 (42.5)
SD	12 (16.4)
PD	3 (4.1)
Median PFS (95%CI)	12.1 (10.9–13.2)
Median OS (95%CI)	15.5 (14.8–16.1)




FIGURE 1: Survival curves: (a) PFS; (b) OS.




FIGURE 2: Comparisons of  $\beta 2$ -MG level in two efficacy groups: (a) CR+PR vs. SD+PD before treatment; (b) CR+PR vs. SD+PD after treatment.




FIGURE 3:  $\beta 2$ -MG level changes in the same group before and after treatment: (a) CR+PR before treatment vs. CR+PR after treatment; (b) SD+PD before treatment vs. SD+PD after treatment.

was downregulated after treatment, but the difference was not statistically significant ( $p > 0.05$ ).

**3.4. Correlation between  $\beta 2$ -MG and Survival Outcome.** We investigated the correlation between  $\beta 2$ -MG expression level before treatment/after treatment/the change rate before and after treatment and the survival outcomes of patients.

Patients were classified into the  $\beta 2$ -MG  $< 3.25$  mg/L group and the  $\beta 2$ -MG  $\geq 3.25$  mg/L group following the median  $\beta 2$ -MG expression level before treatment. The survival analysis of PFS and OS depicted that the difference between two groups was not statistically significant (PFS:

$p > 0.05$ ; OS:  $p > 0.05$ ) (Figure 4). Following the median  $\beta 2$ -MG expression level after treatment, patients were grouped into the  $\beta 2$ -MG  $< 2.77$  mg/L group and the  $\beta 2$ -MG  $\geq 2.77$  mg/L group. The survival analysis of PFS and OS disclosed that the difference between two groups was not statistically significant (PFS:  $p > 0.05$ ; OS:  $p > 0.05$ ) (Figure 5). Following the change rate of  $\beta 2$ -MG expression level before and after treatment (Figure 6), patients were sorted into the change rate  $< 0$  group and the change rate  $> 0$  group. PFS and OS survival analysis denoted that there was no significant difference between two groups (PFS:  $p > 0.05$ ; OS:  $p > 0.05$ ).




FIGURE 4: Subgroup survival curves of patients before treatment: (a) PFS of the  $\beta 2\text{-MG} < 3.25$  mg/L group (blue) and the  $\beta 2\text{-MG} \geq 3.25$  mg/L group (red); (b) OS of the  $\beta 2\text{-MG} < 3.25$  mg/L group and the  $\beta 2\text{-MG} \geq 3.25$  mg/L group.




FIGURE 5: Subgroup survival curves of patients after treatment: (a) PFS of the  $\beta 2\text{-MG} < 2.77$  mg/L group (blue) and the  $\beta 2\text{-MG} \geq 2.77$  mg/L group (red); (b) OS of the  $\beta 2\text{-MG} < 2.77$  mg/L group and the  $\beta 2\text{-MG} \geq 2.77$  mg/L group.

In addition, multivariate Cox regression analysis was carried out according to sex, age, indolent B-cell lymphoma subtype, stage, ECOG PS, number of previous lines of therapy, and  $\beta 2\text{-MG}$  level. As detailed in Table 3, indolent B-cell lymphoma subtype was the independent prognostic marker most likely to affect PFS of patients.

3.5. AEs. The incidence of any grade of AEs in all patients was 32.9% (24/73). Most patients suffered multiple AEs, and these symptoms improved after corresponding treatment. Among them, leukopenia (6 cases), pulmonary infections (4 cases), fever (3 cases), fatigue (4 cases), nausea and emesis (3 cases), and skin rash (1 case) are the major AEs

(Table 4). After reverification, there were 5 cases of severe hematological AEs (grade 3-4), 1 case of obvious nausea and emesis. The incidence of serious AEs was 8.2% (6/73). No patients stopped medication or adjusted dose due to adverse drug reactions during this period.

#### 4. Discussion

Aggressive and indolent lymphomas are the two subtypes of B-cell-derived NHL, which are usually treated with different regimens. We retrospectively analyzed the clinical outcomes of 73 patients with B-cell-associated iNHL. It was unraveled that the BR regimen had good efficacy and safety in B-cell-






FIGURE 6: Subgroup survival curves of the  $\beta 2$ -MG expression change rate: (a) PFS of the change rate < 0 group (blue) and the change rate > 0 group (red); (b) OS of the change rate < 0 group and the change rate > 0 group.

TABLE 3: Multivariate Cox regression analysis.

Variable	PFS		OS	
	HR (95%CI)	p value	HR (95%CI)	p value
Sex (female vs. male)				
Age ( $\leq 60$ vs. $> 60$ )				
Type (B-cell associated indolent lymphoma vs. Mantle cell lymphoma)	2.645 (0.995-7.026)	0.051		
Stage (I-II stage vs. III-IV stage)				
ECOG PS (0-1 vs. $\geq 2$ )				
Number of treatment lines (first-line vs. $\geq$ second-line or later)				
$\beta 2$ -MG ( $> 3.5$ mg/L vs. $\leq 3.5$ mg/L)				

OS. HR (95%CI). p value.

TABLE 4: All-grade AEs.

Toxicities during BR	Major AEs* (%)	Grade 3-4 AEs (%)
Nausea and emesis	3 (4.1)	1 (1.4)
Leukopenia	6 (8.2)	5 (6.8)
Fatigue	4 (5.5)	
Infections	4 (5.5)	
Fever	3 (4.1)	
Rash	1 (1.4)	

\*: Major AEs include any grade of adverse events.

associated iNHL patients. Besides, we investigated the clinical significance of  $\beta 2$ -MG in B-cell-associated iNHL. Unfortunately, based on research samples in this study,  $\beta 2$ -MG does not seem to be able to guide these patients to receive the prognosis after the BR regimen, which may be caused by small sample size, because the BR regimen has just been applied in clinical practice in China not long ago.

At present in China, the R-CHOP regimen remains a standard therapy for most NHL patients, including B-cell-associated iNHL. In the BRIGHT study [13], clinical efficacy

and safety of the R-CHOP/R-CVP or BR regimen in the first-line treatment of B-cell-associated iNHL were compared, and the efficacy of the BR regimen for the long-term clinical benefit of patients was proved. Both bendamustine and cyclophosphamide belong to alkylating agents, but some scholars believed that bendamustine can repress mitotic checkpoint protein to interrupt or stop cell division of cancer cells [22]. Further clarification of the pharmacological mechanism of bendamustine in antitumor may unveil differences in clinical benefits between R-CHOP and BR regimens in the management of B-cell-associated iNHL. A prospective, multicenter, open-label, single-arm, phase 3 study demonstrated the efficacy and safety of bendamustine in Chinese adults with indolent B-cell NHL who relapsed after chemotherapy and rituximab treatment, with results similar to those of previous clinical trials conducted in patients from Western countries [23], which seems to be in line with our results. It is worth noting that the average PFS and OS of the patients in this study were 12.1 months and 15.5 months, respectively, which remains various from the results obtained in the above prospective study. The difference in survival outcomes may be explained by the bias brought about by highly selective patients. In summary, our

investigations provide evidence of clinical efficacy of the BR regimen for Chinese B-cell-associated iNHL patients.

Although extensive research has been carried out on treatment for specific NHL, few studies explore the impact of NHL subgroups on clinical efficacy. The clinical efficacy of the BR regimen is a controversial and much-disputed subject. In the first-line treatment of patients with FL grade 3A, R-CHOP is superior to the BR regimen [24]. While another study disclosed that BR has less toxicity than R-CHOP, which can remarkably decrease recurrence rate and prolong PFS [25]. A recent retrospective study [26] assessed the efficacy and safety of BR and chlorambucil (Chl)-R in untreated CLL patients. Compared with the BR regimen, the Chl-R regimen achieves similar ORR, PFS, time to retreatment (TTR), and OS, but as a result of heterogeneity and extra-heterogeneity toxicities of bendamustine, the dose of the BR regimen is less than that of the Chl-R regimen. This result is consistent with our results. Previous research discussed the clinical efficacy of various lymphomas. Moreover, our research included patients with different subgroups, and some patients had received antitumor therapy previously. Nonetheless, our research failed to unveil the impact of multiline treatment on the survival of patients.

Besides, multivariate Cox regression analysis disclosed that subtype was a factor that affected prognosis. But  $\beta 2$ -MG levels before and after treatment are unable to predict a patient's prognosis well. The reasons may be related to multiplex subtypes and multiline treatment regimens. On the other hand, the results vary in different studies concerning the optimal critical value of  $\beta 2$ -MG as a predictor [27], which may be due to distinct test methods. Considerably more work will need to be done on this issue.

This study was subjected to certain limitations. First, it was a retrospective study with a relatively low level of evidence. Besides, it was a single-arm study that could not be compared with current research programme. Second, this study was limited by small sample size, especially in various histological subtypes of B-cell-associated iNHL. A study [28] unraveled that BR has favorable clinical efficacy as a first-line treatment in unfit patients without TP53 disruption. Nevertheless, this study was limited by a lack of information such as gene mutations in patients. Third, the optimal dose of the BR regimen needs to be warranted. Finally, short follow-up time led to inaccuracy in judging survival of patients after BR regimen.

To put it succinctly, this study authenticated that the BR regimen had favorable efficacy and safety in patients with B-cell-associated iNHL. Though the  $\beta 2$ -MG level did not play a prognostic role in this study, its potential value will be further determined in future studies. Overall, the findings of this study have a number of pivotal implications for future practice of the BR regimen for Chinese patients. Further research in clinical is, therefore, an essential next step in ascertaining the optimal therapeutic regimen.

## Data Availability

The data used to support the findings of this study are included within the article. The data and materials in the

current study are available from the corresponding author on reasonable request.

## Ethical Approval

This study was conducted in accordance with the Helsinki Declaration II and was approved by the Institutional Review Boards of The First Affiliated Hospital, Zhejiang University School of Medicine.

## Consent

Written informed consent was obtained from individual or guardian participants.

## Disclosure

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Conflicts of Interest

The authors declare no conflicts of interest.

## Authors' Contributions

All authors contributed to data analysis, drafting, and revising the article, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

## Acknowledgments

This study was supported by the funds from the Zhejiang Provincial Department of Education general scientific research projects (Y202043474) and the Medical and Health Science and Technology Project of Zhejiang Province (Project No. 2021KY143).

## References

- [1] Global Burden of Disease Cancer Collaboration, C. Fitzmaurice, D. Abate et al., "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017," *Oncologia*, vol. 5, no. 12, pp. 1749–1768, 2019.
- [2] M. van den Brand, B. Scheijen, C. J. Hess, J. H. J. van Krieken, and P. Groenen, "Pathways towards indolent B-cell lymphoma – etiology and therapeutic strategies," *Blood Reviews*, vol. 31, no. 6, pp. 426–435, 2017.
- [3] D. Ribes, H. E. L. Hachem, L. Oberic et al., "Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance," *American Journal of Hematology*, vol. 93, no. 3, pp. 356–362, 2018.
- [4] L. H. Sehn, "Introduction to a review series: the paradox of indolent B-cell lymphoma," *Blood*, vol. 127, no. 17, pp. 2045–2046, 2016.
- [5] A. J. Olszewski, J. N. Butera, J. L. Reagan, and J. J. Castillo, "Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell

- lymphoma,” *American Journal of Hematology*, vol. 95, no. 4, pp. 354–361, 2020.
- [6] M. Teramoto, T. Sone, K. Takada et al., “Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study,” *Rinshō Ketsueki*, vol. 61, no. 6, pp. 598–604, 2020.
- [7] W. Munakata and K. Tobinai, “The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma,” *Expert Opinion on Drug Discovery*, vol. 11, no. 11, pp. 1123–1130, 2016.
- [8] W. U. Knauf, T. Lissichkov, A. Aldaoud et al., “Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia,” *Journal of Clinical Oncology*, vol. 27, no. 26, pp. 4378–4384, 2009.
- [9] K. S. Robinson, M. E. Williams, R. H. van der Jagt et al., “Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma,” *Journal of Clinical Oncology*, vol. 26, no. 27, pp. 4473–4479, 2008.
- [10] T. S. Lin, K. A. Blum, D. B. Fischer et al., “Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders,” *Journal of Clinical Oncology*, vol. 28, no. 3, pp. 418–423, 2010.
- [11] M. J. Rummel, N. Niederle, G. Maschmeyer et al., “Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial,” *Lancet*, vol. 381, no. 9873, pp. 1203–1210, 2013.
- [12] I. W. Flinn, R. van der Jagt, B. S. Kahl et al., “Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study,” *Blood*, vol. 123, no. 19, pp. 2944–2952, 2014.
- [13] I. W. Flinn, R. van der Jagt, B. Kahl et al., “First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study,” *Journal of Clinical Oncology*, vol. 37, no. 12, pp. 984–991, 2019.
- [14] P. Ghia, A. Pluta, M. Wach et al., “ASCEND: phase III, randomized trial of acalabrutinib versus Idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia,” *Journal of Clinical Oncology*, vol. 38, no. 25, pp. 2849–2861, 2020.
- [15] M. Darwish, J. M. Burke, E. Hellriegel et al., “An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma,” *Cancer Chemotherapy and Pharmacology*, vol. 73, no. 6, pp. 1119–1127, 2014.
- [16] Y. Kanemasa, T. Shimoyama, Y. Sasaki et al., “Beta-2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma,” *Hematological Oncology*, vol. 35, no. 4, pp. 440–446, 2017.
- [17] S. H. Swerdlow, E. Campo, S. A. Pileri et al., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” *Blood*, vol. 127, no. 20, pp. 2375–2390, 2016.
- [18] B. D. Cheson, R. I. Fisher, S. F. Barrington et al., “Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification,” *Journal of Clinical Oncology*, vol. 32, no. 27, pp. 3059–3067, 2014.
- [19] K. R. Rai, A. Sawitsky, E. P. Cronkite, A. D. Chanana, R. N. Levy, and B. S. Pasternack, “Clinical staging of chronic lymphocytic leukemia,” *Blood*, vol. 46, no. 2, pp. 219–234, 1975.
- [20] J. L. Binet, A. Auquier, G. Dighiero et al., “A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis,” *Cancer*, vol. 48, no. 1, pp. 198–206, 1981.
- [21] B. D. Cheson, B. Pfistner, M. E. Juweid et al., “Revised response criteria for malignant lymphoma,” *Journal of Clinical Oncology*, vol. 25, no. 5, pp. 579–586, 2007.
- [22] K. P. Garnock-Jones, “Bendamustine,” *Drugs*, vol. 70, no. 13, pp. 1703–1718, 2010.
- [23] Y. K. Shi, X. N. Hong, J. L. Yang et al., “Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study,” *Chinese Medical Journal*, vol. 134, no. 11, pp. 1299–1309, 2021.
- [24] M. Pouiourou, A. Meyer, A. Stroux et al., “First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis,” *Annals of Hematology*, vol. 99, no. 12, pp. 2821–2829, 2020.
- [25] P. Mondello, N. Steiner, W. Willenbacher et al., “Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study,” *The Oncologist*, vol. 23, no. 4, pp. 454–460, 2018.
- [26] F. Autore, I. Innocenti, F. Corrente et al., “Front-line therapy for elderly chronic lymphocytic leukemia patients: bendamustine plus rituximab or chlorambucil plus rituximab? Real-life retrospective multicenter study in the Lazio region,” *Frontiers in Oncology*, vol. 10, p. 848, 2020.
- [27] M. Sorigue, M. Bishton, E. Domingo-Domenech et al., “Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma,” *Leukemia & Lymphoma*, vol. 60, no. 10, pp. 2524–2531, 2019.
- [28] A. Cuneo, A. R. Mato, G. M. Rigolin et al., “Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study,” *Cancer Medicine*, vol. 9, no. 22, pp. 8468–8479, 2020.